| Drug ID: | Drug165 |
|---|---|
| Drug Name: | Cobitolimod |
| CID: | 121492440 |
| DrugBank ID: | DB14819 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT01493960, , NCT05404074, , NCT04985968, , NCT03178669 |
| Molecular Formula: | C185H233N73O106P18S6 |
| Molecular Weight: | 5925.0 g/mol |
| Isomeric SMILES: | CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=O)(O)O[C@H]6C[C@@H](O[C@@H]6COP(=O)(O)O[C@H]7C[C@@H](O[C@@H]7COP(=S)(O)O[C@H]8C[C@@H](O[C@@H]8COP(=S)(O)O[C@H] |
| Synonyms: | Cobitolimod; Kappaproct; Cobitolimod [INN]; Cobitolimod [USAN]; Cobitolimod [WHO-DD]; DIMS 0150; Cobitolimod [USAN:INN:WHO-DD]; IDX 0150; UNII-328101264R; WHO 10066 |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
No molecular structure data available
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05404074 | Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis | PHASE1 | UNKNOWN | InDex Pharmaceuticals | Ulcerative Colitis | DRUG: Cobitolimod 500mg | Details |
| NCT04985968 | The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis | PHASE3 | TERMINATED | InDex Pharmaceuticals | Ulcerative Colitis | DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… | Details |
| NCT03178669 | The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis | PHASE2 | COMPLETED | InDex Pharmaceuticals | Ulcerative Colitis | DRUG: cobitolimod|DRUG: Placebo | Details |
| NCT01493960 | The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients | PHASE3 | COMPLETED | InDex Pharmaceuticals | Colitis, Ulcerative | DRUG: Cobitolimod|DRUG: Placebo | Details |
| EUCTR2021-002549-13-SK | A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants with Moderate to Severe Active | PHASE3 | Not Recruiting | InDex Pharmaceuticals AB | Moderate to Severe left-sided Active Ulcerative C… | Product Name: CobitolimodPharmaceutical Form: Rec… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a …
PMID: 33031757
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Cobitolimod is a topically administered, DNA-based oligonucleotide that activates Toll-like receptor 9 (TLR9), and previous research has …
The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages a…
PMID: 31630153
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: The topically applied Toll-like receptor 9 [TLR9] agonist cobitolimod is a first-in-class DNA-based oligonucleotide with demonst…